CoChat
Sign Up
Cited by 134Immune Response and InflammationImmunotoxicology and immune responsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice

Open access
Matthys, P, Mitera, T, Heremans, H, Van Damme, J, Billiau, A·1995·Infection and Immunity
DOI 10.1128/iai.63.4.1158-1164.1995PMC PMC173128
Open this paper in CoChat — free accountOpen PDF

Abstract

Administration of staphylococcal enterotoxin B (SEB) to BALB/c mice was found to induce a cytokine release syndrome hallmarked by weight loss and hypoglycemia. A neutralizing monoclonal antibody against gamma interferon (IFN-gamma) given before SEB counteracted weight loss and prevented hypoglycemia. This protective effect of anti-IFN-gamma antibody was associated with decreased IFN-gamma levels in serum; tumor necrosis factor (TNF) and interleukin-6 (IL-6) levels remained unchanged. A monoclonal anti-IL-6 antibody, known for its ability to cause accumulation of biologically active IL-6 in the circulation, did not modify SEB-induced body weight loss or hypoglycemia. Levels of TNF, IFN-gamma, and IL-6 in serum were all more elevated in anti-IL-6-treated mice than in corresponding SEB-challenged control mice. In D-galactosamine-sensitized mice, SEB-induced weight loss but not hypoglycemia was more severe, resulting mostly in death within 24 h. Higher levels of biologically active TNF and IFN-gamma in serum were noted in these mice than in mice receiving SEB only. In D-galactosamine-sensitized mice, anti-IFN-gamma antibody did prevent hypoglycemia but failed to reduce the severity of the syndrome. Again, TNF levels in anti-IFN-gamma-treated mice remained unchanged. Pretreatment with anti-IL-6 antibody temporarily attenuated SEB-induced hypoglycemia in sensitized mice. Thus, at 6 h post-SEB injection, anti-IL-6-treated mice were less hypoglycemic than corresponding controls. However, at 24 h, hypoglycemia was significantly aggravated. Concomitantly, IL-6 levels were dramatically increased. Neither anti-IFN-gamma nor anti-IL-6 antibody treatment modulated mortality levels in D-galactosamine-sensitized mice. The data obtained with anti-IFN-gamma antibody clearly indicate that endogenous IFN-gamma is instrumental in bringing about hypoglycemia and body weight loss in mice exposed to SEB but also that hypoglycemia is not a crucial determinant of mortality in D-galactosamine-sensitized mice. The data obtained with anti-IL-6 antibody indicate that endogenous IL-6 is involved in regulating the levels of TNF and IFN-gamma in serum.

Overview

Integrity signals

Registry

Crossref · 10.1128/iai.63.4.1158-1164.1995

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 26 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Matthys, P., Mitera, T., Heremans, H., Van Damme, J., & Billiau, A.
Affiliations
  • Rega Institute for Medical Research (BE)
  • Laboratory of Immunobiology, Rega Institute, University of Leuven, Belgium.
ORCID
Venue
Infection and Immunity
Publisher
American Society for Microbiology
Published
1995-04
Volume
63
Issue
4
Pages
1158-1164
ISSN
  • 0019-9567 (ISSN-L)
  • 1098-5522
DOI
10.1128/iai.63.4.1158-1164.1995
PMC
PMC173128
OpenAlex
W1905898110
Cited by
134
References
26
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 3 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 8 · 2013: 5 · 2012: 6
FWCI
3.16
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Infection and Immunity (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
staphylococcal enterotoxin B, cytokine release syndrome, interferon-gamma, interleukin-6, TNF-α, anti-IFN-gamma monoclonal antibody, anti-IL-6 monoclonal antibody, D-galactosamine sensitization, hypoglycemia, weight loss, cytokine production, mortality, endotoxin
MeSH terms
Animals, Body Weight, Diarrhea, Enterotoxins, Galactosamine, Hypoglycemia, Immunologic Techniques, Interferon-gamma, Mice, Inbred BALB C, Time Factors, Tumor Necrosis Factor-alpha, Interleukin-6, Cytokines, Superantigens, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review